Results 11 to 20 of about 178,284 (250)

The role of R21 expression in differential diagnosis of melanocytic lesions

Indian Journal of Pathology and Microbiology, 2023
Background: Cyclic adenosine monophosphate (cAMP) is an intracellular signal transmitter involved in the regulation of melanocyte growth, proliferation, and melanogenesis.
Didem Turcan, Özgül Paşaoğlu, Deniz Arik   +2 more
doaj   +4 more sources

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Lancet, The
Summary Background Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso.
Djibrilla Issiaka, Alison Lawrie, Lisa Stockdale   +2 more
exaly   +4 more sources

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context [PDF]

BMJ Global Health
Background The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. The vaccine will soon be deployed at scale in sub-Saharan Africa.
Jayne Webster, Brian Greenwood, Daniel Chandramohan, Alassane Dicko, Issaka Sagara, Djibrilla Issiaka, Adrian VS Hill, Halimatou Diawara, Fatoumata Koita, Seydou Traoré, Jane Grant, Mehreen Datoo, Mala Sylla, Abdrahmane Boncane Dicko   +13 more
doaj   +3 more sources

Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond

Expert Review of Vaccines, 2023
Andrea A Berry
exaly   +6 more sources

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings. [PDF]

Front Immunol
There is great interest in combining the licensed pre-erythrocytic malaria vaccine R21/Matrix-M(R) and the blood-stage candidate vaccine RH5.1/Matrix-M(R) to maximise efficacy against Plasmodium falciparum malaria.
Bundi CK, Muñoz O, Kibwana E, Bellamy D, Stockdale L, Barrett JR, McHugh K, Mtaka I, Kalinga W, Kimani D, Nyamako L, Keter K, Ogwang R, Hill AVS, Bejon P, Hamaluba M, Silk SE, Minassian AM, Draper SJ, Olotu AI, Kapulu MC, Ewer KJ, Nielsen CM.   +22 more
europepmc   +4 more sources

Psychological correlates of eating behavior in overweight/obese adolescents in Taiwan: Psychometric and correlation analysis of the Three-Factor Eating Questionnaire (TFEQ)-R21

Pediatrics and Neonatology, 2021
Background: The Three-Factor Eating Questionnaire (TFEQ) is a self-assessment scale used widely in the studies of eating behavior, but its short form TFEQ-R21 has not been validated in the Taiwanese population.
Yu-Wen Lin, Chung-Ying Lin, Carol Strong, Chih-Hsiang Liu, Yi-Ping Hsieh, Yi-Ching Lin, Meng-Che Tsai   +6 more
doaj   +3 more sources

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

Trials
Introduction Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools.
Edgard D. Dabira, H. Magloire Natama, Fatou Jaiteh, Koen Peeters Grietens, Fadima Y. Bocoum, Mamadou Ousmane Ndiath, Nuredin Mohammed, Balla Gibba, Adrian V S Hill, Azra Ghani, Annette Erhart, Halidou Tinto, Umberto D’Alessandro   +12 more
doaj   +4 more sources

R21/Matrix-M™ malaria vaccine: a new tool to achieve WHO’s goal to eliminate malaria in 30 countries by 2030?

Journal of Travel Medicine, 2023
A potential breakthrough in the fight against malaria is the availability of a new promising tool, the R21/Matrix-M™ malaria vaccine that has shown an efficacy of 75% to protect young children against clinical malaria in different epidemiological ...
Genton Blaise
exaly   +3 more sources

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial [PDF]

Lancet Infectious Diseases, The, 2022
BACKGROUND Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population ...
Alison Lawrie, Gregory Glenn, Louis Fries   +2 more
exaly   +3 more sources

Examination of the Eating Behavior of the Hungarian Population Based on the TFEQ-R21 Model [PDF]

Nutrients, 2020
Several theories have emerged to study types of eating behavior leading to obesity, but most of the applied models are mainly related to food choice decisions and food consumer behavior. The purpose of this paper was to examine the eating attitudes of Hungarian consumers by applying the Three-Factor Eating Questionnaire (TFEQ-R21).
Zoltan Szakály, Bence Kovacs, Mark Szakály   +2 more
exaly   +4 more sources